The US Food and Drug Administration commissioner nominee may have unintentionally got on the wrong side of some of his future colleagues with a seemingly benign comment about biosimilars and transparency.
During his 20 November confirmation hearing with the Senate Health, Education, Labor and Pensions Committee, Hahn was asked about his...